Status:
COMPLETED
Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy
Lead Sponsor:
Guangdong Provincial People's Hospital
Conditions:
Sodium Zirconium Cyclosilicate
Hyperkalemia
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
Sodium zirconium cyclosilicate (SZC) has been demonstrated for its serum potassium-lowering efficacy and safety in hyperkalemia hemodialysis patients. However, the effects of SZC during the periopera...
Detailed Description
Secondary Hyperparathyroidism (SHPT) is a common and severe manifestation of chronic kidney disease (CKD), especially in end-stage renal disease (ESRD) patients. SHPT is characterized by elevated para...
Eligibility Criteria
Inclusion
- Secondary Hyperparathyroidism (SHPT) is a common and severe manifestation of chronic kidney disease (CKD), especially in end-stage renal disease (ESRD) patients. ESRD MHD with SHPT patients were recruited into this study
Exclusion
- Patients with severe cardiovascular disease who cannot tolerate general anesthesia surgery were not included in this study.
Key Trial Info
Start Date :
November 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT05382988
Start Date
November 1 2016
End Date
December 1 2021
Last Update
May 19 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.